5 Comments
User's avatar
Abram Giller's avatar

Interesting - I wonder what the future outlook is, if China's total sum of initiated clinical trials will outgrow the US's or if they will maintain a neck to neck number. Would also be interesting to see total amount of drugs that reach market in China vs. the US.

Expand full comment
Dylan Riffle's avatar

Yea so far, we’ve only seen half the story. The real question is: just because you can do a Phase I faster and cheaper somewhere else, will it actually translate into equal or better efficiency all the way through to the clinic?

Expand full comment
Al Dente's avatar

You've reported on the quantity of trials. What about their quality?

Expand full comment
Tom's avatar

What is the connection between China approving high quality trial data from overseas and increasing clinic trial counts within China? Did I miss the connection made?

Expand full comment
Kashish's avatar

This was quite an insightful read! It will be interesting to see how the data will look in a couple of years from now. How will other Southeast nations fit in the picture? What will be the impact of current policy decisions in the USA? I believe it will be heavily influenced by the current geopolitical climate.

Expand full comment